X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs STERLING BIOTECH - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA STERLING BIOTECH TORRENT PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 29.6 -2.0 - View Chart
P/BV x 5.6 0.1 7,368.5% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 TORRENT PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
STERLING BIOTECH
Dec-13
TORRENT PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,76811 16,836.2%   
Low Rs1,1863 34,870.6%   
Sales per share (Unadj.) Rs346.126.8 1,291.1%  
Earnings per share (Unadj.) Rs55.2-15.0 -368.9%  
Cash flow per share (Unadj.) Rs73.3-5.5 -1,341.9%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs257.154.9 468.4%  
Shares outstanding (eoy) m169.22267.87 63.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.30.3 1,645.6%   
Avg P/E ratio x26.8-0.5 -5,760.3%  
P/CF ratio (eoy) x20.1-1.3 -1,583.3%  
Price / Book Value ratio x5.70.1 4,536.1%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m249,8871,862 13,422.5%   
No. of employees `00011.81.4 870.1%   
Total wages/salary Rs m9,934547 1,816.8%   
Avg. sales/employee Rs Th4,971.55,303.3 93.7%   
Avg. wages/employee Rs Th843.2403.8 208.8%   
Avg. net profit/employee Rs Th792.4-2,959.0 -26.8%   
INCOME DATA
Net Sales Rs m58,5697,181 815.6%  
Other income Rs m2,23343 5,241.8%   
Total revenues Rs m60,8027,223 841.8%   
Gross profit Rs m13,773947 1,454.5%  
Depreciation Rs m3,0692,543 120.7%   
Interest Rs m2,0564,377 47.0%   
Profit before tax Rs m10,881-5,931 -183.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545-1,924 -80.3%   
Profit after tax Rs m9,336-4,007 -233.0%  
Gross profit margin %23.513.2 178.3%  
Effective tax rate %14.232.4 43.8%   
Net profit margin %15.9-55.8 -28.6%  
BALANCE SHEET DATA
Current assets Rs m53,84114,335 375.6%   
Current liabilities Rs m31,61249,809 63.5%   
Net working cap to sales %38.0-494.0 -7.7%  
Current ratio x1.70.3 591.8%  
Inventory Days Days97403 24.1%  
Debtors Days Days84171 49.1%  
Net fixed assets Rs m42,07955,432 75.9%   
Share capital Rs m846268 315.9%   
"Free" reserves Rs m42,65513,935 306.1%   
Net worth Rs m43,50114,701 295.9%   
Long term debt Rs m22,4089,478 236.4%   
Total assets Rs m101,25073,988 136.8%  
Interest coverage x6.3-0.4 -1,773.0%   
Debt to equity ratio x0.50.6 79.9%  
Sales to assets ratio x0.60.1 596.0%   
Return on assets %11.30.5 2,246.2%  
Return on equity %21.5-27.3 -78.7%  
Return on capital %19.6-6.4 -305.5%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m20,0661,860 1,079.0%   
Fx outflow Rs m5,30425 21,310.2%   
Net fx Rs m14,7621,835 804.5%   
CASH FLOW
From Operations Rs m10,1271,719 589.2%  
From Investments Rs m-7,869-3,148 250.0%  
From Financial Activity Rs m-1,9181,426 -134.5%  
Net Cashflow Rs m212-3 -6,220.6%  

Share Holding

Indian Promoters % 71.5 33.9 210.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.0 -  
FIIs % 12.6 9.9 127.3%  
ADR/GDR % 0.0 16.9 -  
Free float % 8.8 39.3 22.4%  
Shareholders   26,511 21,482 123.4%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   CIPLA  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  PFIZER  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 24, 2018 09:21 AM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS